Resistance to Vitamin D or Parathyroid Hormone
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients with confirmed or suspected conditions with a resistance to vitamin D or parathyroid hormone (PTH) will be admitted for diagnosis and treatment, and inclusion in other studies pertaining to similar conditions.
This study will provide information about problems relating to calcium in the blood, urine, and bones. Patients in this study will undergo a general evaluation / check-up to give researchers an idea of each person's condition or disease. Patients will receive treatment based on their diagnosis and asked to provide specimen samples for further research studies.
| Condition |
|---|
|
Hypocalcemia Osteomalacia Pseudohypoparathyroidism Pseudo-Pseudohypoparathyroidism Rickets |
| Study Type: | Observational |
| Official Title: | Studies of States With Resistance to Vitamin D and Parathyroid Hormone |
| Estimated Enrollment: | 99999999 |
| Study Start Date: | September 1989 |
Patients with confirmed or suspected states with resistance to vitamin D or parathyroid hormone (PTH) will be admitted for diagnosis and treatment and for inclusion in other protocols. These states include hypocalcemia, rickets, osteomalacia, pseudohypoparathyroidism. Resistance to a factor is manifested by deficient bioeffect despite high levels of the factor in blood. Patients will be tested with multiple indices of mineral metabolism to establish the diagnosis and examine the spectrum of the underlying disorder. The principal therapies will be combinations of calcium, phosphate, and a vitamin D analog. Selected patients will have localization and surgery to remove a tumor that causes renal wasting of phosphate. Patients will be considered for entry into other research protocols.
Eligibility| Ages Eligible for Study: | 1 Year and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
Patients of any age or sex with vitamin D resistance, rickets, osteomalacia, pseudohypoparathyroidism, pseudo-pseudohypoparathyroidism, or suspicion of these or related disorders based upon the appropriateness of their problem to ongoing investigations.
Current investigations are focused primarily upon subjects with target tissue resistance to 1,25-dihydroxyvitamin D, pseudohypoparathyroidism, and pseudo-pseudohypoparathyroidism.
Contacts and Locations| Contact: Lee S Weinstein, M.D. | (301) 402-2923 | leew@mail.nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 prpl@mail.cc.nih.gov | |
| Principal Investigator: | Lee S Weinstein, M.D. | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00001242 History of Changes |
| Other Study ID Numbers: | 890173, 89-DK-0173 |
| Study First Received: | November 3, 1999 |
| Last Updated: | May 1, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
Calcium Vitamin D Calcitriol |
Parathyroid Cyclic AMP Rickets |
Additional relevant MeSH terms:
|
Rickets Hypocalcemia Osteomalacia Pseudohypoparathyroidism Pseudopseudohypoparathyroidism Calcium Metabolism Disorders Metabolic Diseases Water-Electrolyte Imbalance Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Vitamin D Deficiency Avitaminosis Deficiency Diseases Malnutrition |
Nutrition Disorders Metal Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Vitamin D Ergocalciferols Vitamins Hormones Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances Hormones, Hormone Substitutes, and Hormone Antagonists |
ClinicalTrials.gov processed this record on June 17, 2013